Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation | Shah, M., A. K. Jain, S. M. Brunelli, S. G. Coca, P. J. Devereaux, M. T. James, J. Luo, et al. 2014. “Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis.” BMC Nephrology 15 (1): 53. doi:10.1186/1471-2369-15-53. http://dx.doi.org/10.1186/1471-2369-15-53. |
| Published Version | doi:10.1186/1471-2369-15-53 |
| Citable link | http://nrs.harvard.edu/urn-3:HUL.InstRepos:12406949 |
| Terms of Use | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis

Mitesh Shah1, Arsh K Jain2,3, Steven M Brunelli4, Steven G Coca5, Philip J Devereaux6,7, Matthew T James8, Jin Luo3, Amber O Molnar9, Marko Mrkobrada10, Neesh Pannu11, Chirag R Parikh5, Michael Paterson3,12, Salimah Shariff4, Ron Wald13, Michael Walsh6,14, Richard Whitlock6,15, Duminda N Wijeysundera3,16 and Amit X Garg2,3,6,17*

Abstract

Background: Some studies but not others suggest angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) use prior to major surgery associates with a higher risk of postoperative acute kidney injury (AKI) and death.

Methods: We conducted a large population-based retrospective cohort study of patients aged 66 years or older who received major elective surgery in 118 hospitals in Ontario, Canada from 1995 to 2010 (n = 237,208). We grouped the cohort into ACEi/ARB users (n = 101,494) and non-users (n = 135,714) according to whether the patient filled at least one prescription for an ACEi or ARB (or not) in the 120 days prior to surgery. Our study outcomes were acute kidney injury treated with dialysis (AKI-D) within 14 days of surgery and all-cause mortality within 90 days of surgery.

Results: After adjusting for potential confounders, preoperative ACEi/ARB use versus non-use was associated with 17% lower risk of post-operative AKI-D (adjusted relative risk (RR): 0.83; 95% confidence interval (CI): 0.71 to 0.98) and 9% lower risk of all-cause mortality (adjusted RR: 0.91; 95% CI: 0.87 to 0.95). Propensity score matched analyses provided similar results. The association between ACEi/ARB and AKI-D was significantly modified by the presence of preoperative chronic kidney disease (CKD) (P value for interaction < 0.001) with the observed association evident only in patients with CKD (CKD - adjusted RR: 0.62; 95% CI: 0.50 to 0.78 versus No CKD: adjusted RR: 1.00; 95% CI: 0.81 to 1.24).

Conclusions: In this cohort study, preoperative ACEi/ARB use versus non-use was associated with a lower risk of AKI-D, and the association was primarily evident in patients with CKD. Large, multi-centre randomized trials are needed to inform optimal ACEi/ARB use in the peri-operative setting.

Keywords: Acute dialysis, Angiotensin converting enzyme inhibitor, Angiotensin receptor blocker, Major elective surgery

Background

Acute kidney injury (AKI) is a serious complication of major surgery and severe AKI requires treatment with acute dialysis [1,2]. Annually 230 million patients undergo major surgery worldwide and around one million major surgeries are complicated by AKI treated with dialysis (AKI-D) [1-4]. The development of AKI is associated with increased morbidity, mortality, and health care expenditures [5]. A patient’s risk for developing postoperative AKI is influenced by a variety of clinical factors including pre-existing comorbidities (e.g. chronic kidney disease (CKD), congestive heart failure, coronary artery disease, diabetes, hypertension), clinical factors around the time of surgery (e.g. volume depletion, blood loss, hypotension, administration of vasoconstrictors), type of surgery (e.g. cardiac, vascular), and certain medications used in the perioperative period (e.g. antihypertensive medications) [2,3,6-10].
Medication use prior to surgery is of particular interest given the possibility of modification prior to planned elective surgeries.

Angiotensin converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) are frequently prescribed medications [11,12]. Despite their demonstrated benefits in outpatient settings, their continued use in the perioperative period remains controversial as preoperative ACEi/ARB use may lead to the development of perioperative hypotension and subsequent AKI [8,13-16]. However, previous observational studies on the association between preoperative ACEi/ARB use and AKI have had conflicting results, and have focused on milder forms of AKI rather than the most serious renal outcome of AKI-D. We conducted this large retrospective cohort study to test the hypothesis that preoperative ACEi/ARB use compared to non-use associates with a different risk of AKI-D following major elective surgery.

Methods

Setting and study overview

We conducted a retrospective, population-based cohort study of patients aged 66 years or older admitted to a hospital for a major elective surgery from 1995 to 2010 in Ontario, Canada. Ontario residents have universal access to hospital care and physician services and those aged 65 years or older have universal prescription drug coverage [17]. We performed this study according to a prespecified protocol approved by the research ethics board at Sunnybrook Health Sciences Centre, Toronto, Canada. The board deemed that patient informed consent was not required for this study which used datasets without patient identifiers. The reporting of this study follows guidelines set out for observational studies (detailed in Additional file 1) [18].

Data sources

We used linked large health care databases including hospital discharge, physician billing, and prescription drug claims databases to determine patients’ characteristics, information on comorbidities, outcome data, and drug usage. The Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD) provides detailed diagnostic and procedural information on all hospitalizations. The Ontario Health Insurance Plan (OHIP) database records all health claims for inpatient and outpatient physician services. The Ontario Registered Persons Database (RPDB) records demographic and vital status information. The Ontario Drug Benefits (ODB) database provides highly accurate information on dispensed outpatient medications [17]. These databases have been used extensively to research health outcomes and health services, including drug-induced and perioperative AKI [3,19-23].

Study population

We included patients aged 66 years or older admitted to a hospital for elective surgery between January 1, 1995 and November 30, 2010. We excluded patients in their first year of universal drug coverage (patients aged 65 years) to avoid incomplete historical medication data. We included five surgical categories: cardiac, vascular, thoracic, abdominal, and retro-peritoneal, which all carry an appreciable risk for AKI-D (sample database codes in Additional file 1) [2,3,6,7,22]. To avoid selecting emergent or urgent surgery, we excluded all surgeries done during the course of a non-surgical hospital admission. We also excluded hospital admissions associated with missing or invalid identification, or demographic information. To ensure all patients had a recent access to health-care services, we limited our analyses to patients with at least one dispensed outpatient medication prescription in the 120 days prior to surgery.

We excluded patients with end-stage renal disease (ESRD) prior to their surgery (i.e. any evidence of dialysis or kidney transplantation) as the assessment of AKI-D is different and may no longer be relevant. To avoid the need to account for less frequently prescribed anti-hypertensive medications in the analyses, we only considered patients with either no evidence of anti-hypertensive medication use, or evidence of a prescription for the following frequently prescribed anti-hypertensive medications in the 120 days prior to surgery: ACEi, ARB, β-blocker, calcium channel blocker, non-potassium sparing diuretic (loop diuretic or thiazide diuretic). For patients with multiple eligible surgeries during the study period, we randomly selected one surgical procedure to avoid within patient clustering in the analyses.

Preoperative ACEi/ARB use

We grouped selected surgical cohort into ACEi/ARB users and non-users according to whether the patient filled at least one prescription for an ACEi or ARB (or not) in the 120 days prior to surgery. We selected a time frame of 120 days because the provincial drug plan requires each prescription to be renewed at least once every 100 days and 20 extra days were considered to accommodate any missed doses resulting in a longer period between renewal [24].

Baseline characteristics

We assessed demographic characteristics and comorbidities using validated database codes whenever possible (detailed in Additional file 1) [25-32]. We also determined concomitant medication use in the 120 days prior to surgery.

Primary and secondary outcomes

Our primary outcome was AKI-D within 14 days of surgery. AKI-D was determined using a set of high performance service fee codes (detailed in Additional file 1). Our
secondary outcome was all-cause mortality within 90 days of surgery (in our data sources the code has a sensitivity of 97.8% and specificity of 100% for the finding of death) [33].

Primary analyses
We performed all statistical analyses at the Institute for Clinical Evaluative Sciences using SAS 9.2 (SAS Institute, Cary, NC, USA). We assessed differences in baseline characteristics between ACEi/ARB users and non-users using standardized differences. As recommended by others, we considered a standardized difference of >10% as a meaningful difference between the two groups [34]. To determine the association between ACEi/ARB use and study outcomes, we conducted multivariable logistic regression analyses and estimated adjusted odds ratios (ORs) and 95% confidence intervals (CIs). We interpreted odds ratios as relative risks (RRs) (appropriate given the incidences observed) [35]. In the logistic regression analyses, we adjusted for the following prespecified baseline characteristics associated with ACEi/ARB use and postoperative AKI [2,3,6-8,10,11,15,36,37]: age, sex, CKD, coronary artery disease, congestive heart failure, cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary disease, chronic liver disease, type of surgery (cardiac, vascular, thoracic, abdominal, retro-peritoneal), era of surgery (1995 to 1998, 1999 to 2001, 2002 to 2004, 2005 to 2007, 2008 to 2010), and use of one or more drugs from the following medication groups - anti-diabetic medications, β-blockers, calcium channel blockers, non-potassium sparing diuretics, and statins. The presence of all these characteristics was assessed with database codes (detailed in Additional file 1).

Additional analyses
Propensity score matching
We derived a propensity score for every patient from all the potential confounders prespecified in our primary analysis. The propensity score indicated the likelihood of receiving a preoperative ACEi/ARB [38,39]. We derived a propensity score using logistic regression analyses and estimated adjusted odds ratios (ORs) and 95% confidence intervals (CIs). We interpreted odds ratios as relative risks (RRs) (appropriate given the incidences observed) [35]. In the logistic regression analyses, we adjusted for the following prespecified baseline characteristics associated with ACEi/ARB use and postoperative AKI [2,3,6-8,10,11,15,36,37]: age, sex, CKD, coronary artery disease, congestive heart failure, cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary disease, chronic liver disease, type of surgery (cardiac, vascular, thoracic, abdominal, retro-peritoneal), era of surgery (1995 to 1998, 1999 to 2001, 2002 to 2004, 2005 to 2007, 2008 to 2010), and use of one or more drugs from the following medication groups - anti-diabetic medications, β-blockers, calcium channel blockers, non-potassium sparing diuretics, and statins. The presence of all these characteristics was assessed with database codes (detailed in Additional file 1).

Subgroup analyses
CKD is a strong risk factor for postoperative AKI [7,10]. We performed sub-group analysis to explore whether pre-existing CKD was an effect modifier of the association between ACEi/ARB use and study outcomes. Additionally, we also performed sub-group analyses for congestive heart failure and diabetes (determined by anti-diabetic medications prescription). We adjusted for all potential confounders included in the primary analyses except the sub-group factor being tested. A P value < 0.05 for the test of interaction was considered statistically significant.

Time to event analysis
We performed multivariable Cox-proportional hazards regression analyses to examine the association between ACEi/ARB use and study outcomes accounting for the time to event. We adjusted for all prespecified potential confounders and estimated the adjusted hazard ratios (HRs) and 95% CIs.

Results
Baseline characteristics: ACEi/ARB users and non-users
We selected 237,208 adult patients from 118 hospitals in Ontario, of whom 101,494 (42.8%) were ACEi/ARB users (Table 1) (selection figure detailed in Additional file 1). ACEi/ARB users, compared to non-users, were more likely to be male and have CKD, cerebrovascular disease, peripheral vascular disease, coronary artery disease, and congestive heart failure. ACEi/ARB users, compared to non-users, were more likely to be on anti-diabetic medications, other anti-hypertensive medications (β-blockers, calcium channel blockers, and non-potassium sparing diuretics), and statins. ACEi/ARB users, compared to non-users, were more likely to undergo cardiac and vascular surgeries. Patients having their surgery in more recent years (2002 to 2010) were more likely to have received ACEi/ARB prior to surgery compared to prior years (1995 to 2001).

Primary analyses: AKI-D and all-cause mortality
After adjusting for potential confounders, preoperative ACEi/ARB use was associated with a lower risk of AKI-D (adjusted RR: 0.83; 95% CI: 0.71 to 0.98) and a lower risk of all-cause mortality (adjusted RR: 0.91; 95% CI: 0.87 to 0.95) (Table 2; associations with all variables in the model are presented in Additional file 1).

Additional analyses
Propensity score matched analyses: AKI-D and all-cause mortality
A total of 67,822 ACEi/ARB users were successfully matched to 67,822 non-users (Table 1). Baseline characteristics were well balanced between matched ACEi/ARB users and non-users (Table 1). Similar to the primary
## Table 1 Baseline characteristics: ACEi/ARB users and non-users

| Demographics | Pre-matched cohort | Propensity matched cohort |
|--------------|-------------------|--------------------------|
|              | ACEi/ARB users    | Non-users                | ACEi/ARB users | Non-users |
|              | N = 101,494       | N = 135,714              | N = 67,822     | N = 67,822 |
| Age at index date (years) | 74 (70 to 78) | 73 (69 to 78) | 74 (70 to 78) | 74 (70 to 78) |
| Age groups (years) |                      |                          |                |            |
| 66 to 70     | 30,557 (30.1%)    | 43,652 (32.2%)           | 20,098 (29.6%) | 20,165 (29.7%) |
| 71 to 75     | 30,966 (30.5%)    | 40,782 (30.0%)           | 20,482 (30.2%) | 20,391 (30.1%) |
| 76 to 80     | 23,898 (23.5%)    | 29,529 (21.8%)           | 15,982 (23.6%) | 15,779 (23.3%) |
| 81 to 85     | 11,812 (11.6%)    | 15,361 (11.3%)           | 8,101 (11.9%)  | 8,205 (12.1%)  |
| 86 to 90     | 3,651 (3.6%)      | 5,294 (3.9%)             | 2,682 (4.0%)   | 2,761 (4.1%)   |
| 91+          | 610 (0.6%)        | 1,096 (0.8%)             | 477 (0.7%)     | 521 (0.8%)     |

| Comorbidities |                    |                          |                |            |
|              | Chronic kidney disease | 7,538 (7.4%) a | 5,027 (3.7%) a | 3,852 (5.7%) | 3,852 (5.7%) |
|              | Coronary artery disease | 67,921 (66.9%) a | 61,137 (45.0%) a | 40,114 (59.1%) | 40,346 (59.5%) |
|              | Congestive heart failure | 22,108 (21.8%) a | 12,413 (9.1%) a | 10,740 (15.8%) | 10,317 (15.2%) |
|              | Cerebrovascular disease | 18,016 (17.8%) a | 17,551 (12.9%) a | 10,970 (16.2%) | 11,097 (16.4%) |
|              | Peripheral vascular disease | 6,490 (6.4%) a | 5,571 (4.1%) a | 3,675 (5.4%) | 3,599 (5.3%) |
|              | COPD | 5,806 (5.7%) | 7,121 (5.2%) | 3,789 (5.6%) | 3,527 (5.2%) |
|              | Chronic liver disease | 295 (0.3%) | 478 (0.4%) | 200 (0.3%) | 194 (0.3%) |

| Medications |                    |                          |                |            |
| Oral hypoglycemic | 21,267 (21.0%) a | 10,381 (7.6%) a | 8,766 (12.9%) | 8,625 (12.7%) |
| Insulin | 6,089 (6.0%) a | 2,381 (1.8%) a | 2,348 (3.5%) | 1,937 (2.9%) |
| Anti-diabetic medicationb | 25,041 (24.7%) a | 12,215 (9.0%) a | 10,364 (15.3%) | 10,076 (14.9%) |
| β-blocker | 44,835 (44.2%) a | 34,096 (25.1%) a | 24,550 (36.2%) | 24,702 (36.4%) |
| Calcium channel blocker | 36,659 (36.1%) a | 32,659 (24.2%) a | 21,630 (31.9%) | 22,131 (32.6%) |
| Diureticc | 40,345 (39.8%) a | 22,042 (16.2%) a | 19,830 (29.2%) | 19,595 (28.9%) |
| Statin | 53,915 (53.1%) a | 31,691 (23.4%) a | 27,348 (40.3%) | 26,913 (39.7%) |

| Surgical characteristics |                    |                          |                |            |
| Type of surgery |                    |                          |                |            |
| Cardiac surgery | 40,694 (40.1%) a | 29,475 (21.7%) a | 22,222 (32.8%) | 22,380 (33.0%) |
| Vascular surgery | 18,459 (18.2%) a | 18,969 (14.0%) a | 11,509 (17.0%) | 11,904 (17.5%) |
| Thoracic surgery | 5,771 (5.7%) | 10,177 (7.5%) | 4,561 (6.7%) | 4,176 (6.2%) |
| Abdominal surgery | 30,821 (30.0%) a | 64,911 (47.8%) a | 24,592 (36.2%) | 24,630 (36.3%) |
| Retro-peritoneal surgery | 6,099 (6.0%) a | 12,812 (9.0%) a | 4,938 (7.3%) | 4,732 (7.0%) |

| Era of surgery |                    |                          |                |            |
| 1995 to 1998 | 14,718 (14.5%) a | 45,173 (33.3%) a | 13,278 (19.6%) | 13,647 (20.1%) |
| 1999 to 2001 | 16,900 (16.6%) a | 30,122 (22.2%) a | 13,457 (19.8%) | 13,963 (20.6%) |
| 2002 to 2004 | 20,960 (20.7%) a | 21,992 (16.2%) a | 13,404 (19.8%) | 13,194 (19.5%) |
| 2005 to 2007 | 23,711 (23.4%) a | 19,520 (14.4%) a | 13,625 (20.1%) | 13,300 (19.6%) |
| 2008 to 2010 | 25,205 (24.8%) a | 18,907 (13.9%) a | 14,058 (20.7%) | 13,718 (20.2%) |

ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; COPD: Chronic obstructive pulmonary disease.

Data are presented as number (percent) except age at index date, which is presented as median (interquartile range). Index date is a surgical procedure date or hospital admission date if the surgical procedure date is not available.

aRepresents a standardized difference of >10% between ACEi or ARB users and non-users and we considered it as a meaningful difference [34]. Standardized difference is less sensitive to sample size compared to traditional hypothesis tests and is calculated by examining the difference between the two groups divided by the pooled standard deviation of the two groups [34].

bAnti-diabetic medication includes oral hypoglycemic and insulin. cDiuretic include loop diuretic and thiazide diuretic. 3.0% (3,091/101,494) patients were on ACEi and ARB.
the outcomes in subgroups of patients defined by the pres-
find a significant interaction between ACEi/ARB use and 
mortality (test of interaction, 
interaction between ACEi/ARB use and CKD for all-cause 
patients with CKD (CKD - adjusted RR: 0.62; 95% CI: 0.50 to 
value < 0.001). The observed benefit was evident in pa-

tions, preoperative ACEi/ARB use was associated with 
a lower risk of AKI-D (RR: 0.77; 95% CI: 0.65 to 0.92) and 
a lower risk of all-cause mortality (RR: 0.93; 95% CI: 0.88 
to 0.97) (Table 3). ACEi/ARB use, compared to non-use, 
was associated with 0.09% (95% CI: 0.03% to 0.16%) absol-
ute risk reduction in AKI-D and 0.35% (95% CI: 0.12% to 
0.57%) absolute risk reduction in all-cause mortality.

Subgroup analyses: AKI-D and all-cause mortality
We found CKD significantly modified the association be-
tween ACEi/ARB use and AKI-D (test of interaction, P 
value < 0.001). The observed benefit was evident in pa-
ients with CKD (CKD - adjusted RR: 0.62; 95% CI: 0.50 to 
0.78 and not in those without CKD: adjusted RR: 1.00; 
95% CI: 0.81 to 1.24) (Table 4). There was no significant 
interaction between ACEi/ARB use and CKD for all-cause 
mortality (test of interaction, P value = 0.26). We did not 
find a significant interaction between ACEi/ARB use and 
the outcomes in subgroups of patients defined by the pre-

cence of congestive heart failure and diabetes (Table 4).

Time to event analyses: AKI-D and all-cause mortality
Similar to the primary analyses, preoperative ACEi/ARB 
use was associated with a lower risk of AKI-D (adjusted 
HR: 0.83; 95% CI: 0.71 to 0.97) and all-cause mortality 
(adjusted HR: 0.91; 95% CI: 0.88 to 0.95).

Discussion
Contrary to the results of other studies, in this analysis 
preoperative ACEi/ARB use versus non-use was associ-
ated with 17% lower risk of AKI-D and 9% lower risk of 
all-cause mortality, when we adjusted for a set of prespe-
cified potential confounders. We found similar results in 
the propensity score matched analyses. The association 
of preoperative ACEi/ARB use versus non-use on AKI-D 
was only evident in patients with CKD.

With respect to mechanism, it is possible that potential 
benefits of ACEi/ARB use in surgical settings relates 
to angiotensin II inhibition [36,40-42]. Angiotensin II is 
a potent vasoconstrictor, which can cause postoperative 
AKI (i.e., true tubular injury) by increasing oxidative 
stress, endothelial dysfunction, inflammatory response, 
and renal vascular resistance, and by reducing renal 
blood flow [36,42]. By inhibiting angiotensin II, ACEi/ 
ARB use may increase the risk of functional AKI (i.e., a 
drop in GFR) but may paradoxically reduce the risk of 
“true AKI” (true tubular injury) [36,40-42]. In this re-

gard, ACEi and ARB may improve renal blood flow and 
oxxygenation to the renal tubules by vasodilatation of ef-
ferrant arterioles and may prevent tubular cell necrosis 
during ischemic insults around surgery [13]. To wit, a 
recent analysis from a large multi-center cohort of pa-

tients undergoing cardiac surgery (TRIBE-AKI cohort) 
showed that while AKI defined by changes in serum 
creatinine, was higher in those that had ACEi or ARB 
continued pre-operatively, there was not a concomitant 
increase in several biomarkers of kidney injury [43]. 
While that study may also suffer confounding by indica-
tion, most impressive is that despite greater comorbid-
ties in patients that continued ACEi/ARB, the kidney 
injury biomarkers still were not more elevated, suggest-
ing some protective benefit of these agents [43].

| Outcomes | No. of patients with events (percent) | Adjusted* RR (95% CI) |
|----------|-------------------------------------|----------------------|
| ACEi/ARB users | Non-users | AKI-D     | All-cause mortality |
| (N = 101,494) | (N = 135,714) | 438 (0.43%) | 4,654 (4.59%) | 0.83 (0.71, 0.98) | 0.91 (0.87, 0.95) |
| AKI-D     | 372 (0.27%) | 6,435 (4.74%) |

ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; RR: Relative Risk; CI: Confidence Interval; ARR: Absolute risk reduction; AKI-D: Acute kidney injury treated with dialysis.

Outcomes: (1) Primary outcome: AKI-D (within 14 days of surgery); (2) Secondary outcome: All-cause mortality (within 90 days of surgery).

Relative risk was calculated for preoperative ACEi or ARB use compared to non-use.

Table 3 Propensity score matched cohort: association between preoperative ACEi/ARB use and outcomes

| Outcomes | No. of patients with events (percent) | RR (95% CI) | ARR (95% CI) |
|----------|-------------------------------------|------------|-------------|
| ACEi/ARB users | Non-users | AKI-D     | All-cause mortality |
| (N = 67,822) | (N = 67,822) | 215 (0.32%) | 3,060 (4.51%) | 0.77 (0.65, 0.92) | 0.09% (0.03%, 0.16%) |
| AKI-D     | 278 (0.41%) | 3,295 (4.86%) |

ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; RR: Relative Risk; CI: Confidence Interval; ARR: Absolute risk reduction; AKI-D: Acute kidney injury treated with dialysis.

Outcomes: (1) Primary outcome: AKI-D (within 14 days after surgery); (2) Secondary outcome: All-cause mortality (within 90 days after surgery).

Relative risk was calculated for preoperative ACEi or ARB use compared to non-use.
Our results are also similar to two small observational studies by Benedetto et al. [40,41] Benedetto et al. studied 536 patients who underwent cardiac surgery and observed a lower risk of AKI with preoperative ACEi use compared to non-use (adjusted OR: 0.48; 95% CI: 0.23 to 0.77) [41]. The authors presumed the pathophysiologic benefit of ACEi use stemmed from the preservation of renal blood flow during surgery [41]. Barodka et al. found similar benefits with preoperative ACEi/ARB use compared to non-use in 346 patients who underwent cardiac surgery (adjusted OR: 0.19; 95% CI: 0.04 to 0.84) [40].

Other observational studies by Rady et al. [44], Ouzounian et al. [37], and Yoo et al. [45], studied 11330, 1647, and 472 cardiac surgery patients, respectively, and demonstrated no significant association between preoperative ACEi/ARB use and AKI. However, all three studies observed a non-significant trend towards a benefit with preoperative ACEi/ARB use raising the possibility of insufficient statistical power to detect the association [37,44,45].

Miceli et al. performed a propensity score matched analysis in 9,274 patients who underwent cardiac surgery and noted a 1.36 fold higher risk of AKI (adjusted OR: 1.36; 95% CI: 1.10 to 1.67) with preoperative ACEi/ARB use compared to non-use and a two-fold higher risk of mortality (adjusted OR: 2.00; 95% CI: 1.17 to 3.42) [8]. The authors speculated that the AKI occurred as a result of a decrease in renal perfusion, mainly due to reduction in mean arterial pressure along with increased use of vasoconstrictors [8]. Both Cittanova et al. and Arora et al. also observed an increased risk of AKI with preoperative ACEi and ARB use, although the study samples were small (249 aortic surgery patients and 1358 cardiac surgery patients, respectively) [11,46]. Railton et al. studied the outcome of AKI-D and observed a higher incidence of AKI-D with ACEi/ARB use compared to non-use in patients who underwent abdominal aortic aneurysm repair (4.6% vs. 0.8%; P value = 0.01) [47]. However, the number of patients (n = 883) and number of events (n = 24) were small [47].

Major considerations when comparing our results with previous studies are the heterogeneous AKI definitions, type of surgery, and the consideration of preoperative CKD in statistical analysis. Our primary outcome was AKI-D, which is the acute renal outcome most important to patients and their health-care providers [1-3,5]. The outcome of AKI-D is distinct from AKI defined solely by acute changes in serum creatinine [48]. The latter is a

Table 4 Influence of chronic kidney disease, congestive heart failure, and diabetes on association between preoperative ACEi/ARB use and outcomes

| Outcomes                  | Presence/absence of comorbid condition | Adjusted* RR (95% CI) | P value (test for interaction) |
|---------------------------|----------------------------------------|-----------------------|--------------------------------|
| AKI-D                     | CKD (Yes)                              | 0.62 (0.50, 0.78)     | < 0.001                        |
|                           | No (No)                                | 1.00 (0.81, 1.24)     |                                |
|                           | CHF (Yes)                              | 0.62 (0.45, 0.85)     | 0.29                           |
|                           | No (No)                                | 0.81 (0.65, 1.00)     |                                |
|                           | Diabetes (Yes)                         | 0.63 (0.43, 0.91)     | 0.56                           |
|                           | No (No)                                | 0.77 (0.63, 0.94)     |                                |
| All-cause mortality       | CKD (Yes)                              | 0.86 (0.75, 0.98)     | 0.26                           |
|                           | No (No)                                | 0.91 (0.87, 0.96)     |                                |
|                           | CHF (Yes)                              | 1.01 (0.91, 1.12)     | 0.06                           |
|                           | No (No)                                | 0.92 (0.86, 0.97)     |                                |
|                           | Diabetes (Yes)                         | 0.96 (0.86, 1.09)     | 0.34                           |
|                           | No (No)                                | 0.93 (0.88, 0.99)     |                                |

ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; RR: Relative risk; CI: Confidence interval; AKI-D: Acute kidney injury treated with dialysis; CKD: Chronic kidney disease; CHF: Congestive heart failure.

Outcomes: (1) Primary outcome: AKI-D (within 14 days after surgery); (2) Secondary outcome: All-cause mortality (within 90 days after surgery).

*CKD sub-group analyses: adjusted for age, sex, coronary artery disease, congestive heart failure, cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary disease, chronic liver disease, anti-diabetic agents, beta-adrenergic blockers, calcium channel blockers, non-potassium sparing diuretics, statins, type of surgery (cardiac, vascular, thoracic, abdominal, retro-peritoneal), era of surgery (1995 to 1998, 1999 to 2001, 2002 to 2004, 2005 to 2007, 2008 to 2010).

*CHF sub-group analyses: adjusted for age, sex, coronary artery disease, chronic kidney disease, cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary disease, chronic liver disease, anti-diabetic agents, beta-adrenergic blockers, calcium channel blockers, non-potassium sparing diuretics, statins, type of surgery (cardiac, vascular, thoracic, abdominal, retro-peritoneal), era of surgery (1995 to 1998, 1999 to 2001, 2002 to 2004, 2005 to 2007, 2008 to 2010).

*Diabetes sub-group analyses: adjusted for age, sex, coronary artery disease, chronic kidney disease, congestive heart failure, cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary disease, chronic liver disease, beta-adrenergic blockers, calcium channel blockers, non-potassium sparing diuretics, statins, type of surgery (cardiac, vascular, thoracic, abdominal, retro-peritoneal), era of surgery (1995 to 1998, 1999 to 2001, 2002 to 2004, 2005 to 2007, 2008 to 2010).
surrogate outcome and may be misleading particularly in the ACEi or ARB setting (i.e. use of these medications in outpatient settings may increase serum creatinine concentration despite evidence that the drugs prevent progression to ESRD requiring chronic maintenance dialysis) [11,49,50].

CKD is considered to be the most important risk factor for AKI [7,10]. However, the majority of previous studies did not account for CKD in their analyses [8,11,37,40,41,44-46]. In this study, we observed an association of less AKI-D with preoperative ACEi/ARB use compared to non-use only in patients with preoperative CKD. One concern interpreting this result is that CKD patients not receiving preoperative ACEi/ARB may represent an advanced disease population where ACEi/ARB might have been stopped due to the risk of early onset chronic maintenance dialysis [51]. Another concern is that we identified CKD patients using database codes which have limited validity. These codes underestimate CKD prevalence may have impacted the study results. Moreover, this prevented us from examining CKD stages according to preferred glomerular filtration rate (eGFR) categories [30,52].

**Study strengths and limitations**

Our study has several strengths. To the best of our knowledge, this is the largest study to describe the association between preoperative ACEi/ARB use and AKI-D (over 230,000 patients from 118 hospitals). We included both cardiac and non-cardiac major surgeries. Unlike other studies, the large number of events of AKI-D (810 events) reduced concerns about statistical overfitting [53]. Given there is <1% yearly emigration from Ontario, the loss to follow up was minimal. Finally, the information available within the large Ontario health care databases reflects routine clinical practice and may be less prone to participation biases that can arise in other types of studies [3,19-23].

There are several limitations to our study. Due to possible difference in underlying mechanism for the risk of postoperative acute dialysis in emergent surgeries compared to elective surgeries, we excluded emergent surgeries from our analyses. In an emergency situation it is also difficult to manipulate pre-operative medication use. However, exclusion of emergency surgeries may have reduced the generalizability of the study results. We could not determine medication compliance from evidence of a dispensed prescription for ACEi, ARB, or other medications in our data sources. Our study was limited by the absence of key information on perioperative ACEi/ARB use particularly whether it was held prior to surgery and if so when it was held, and when it was restarted after surgery. Important information such as preoperative and intraoperative blood pressure was also not available. These are key elements to guide the optimal and safe use of ACEi/ARB use in the perioperative period, including regimens to be tested in large randomized controlled trials (RCTs).

We were also not able to adjust for variables unavailable in our data sources such as body mass index, preoperative proteinuria, non-prescription medication use and in hospital medication use. Another limitation with our data sources is the accuracy of codes for patient related health information. In attempt to limit these concerns, we did use database codes supported by validation studies whenever possible [25-32].

**Study implications and future directions**

Our study results support the need for RCTs in this setting, to test a regimen of perioperative ACEi/ARB selected for optimal efficacy and safety. Given the low incidence of acute dialysis (about 0.45% in all types of major surgery [1-3]), a very large trial (over 150,000 patients) would be needed to examine a meaningful difference with this as a primary outcome. Such a trial is unlikely to occur. However, if we consider a primary outcome of 90-day all-cause mortality (4.67% of patients in our study), the sample size is tenable at about 15,000 patients. The sample size could be further reduced if there is a rationale to consider a composite of clinically important events including perioperative cardiac events. Enrolling a large number of patients with CKD may be prudent, as in the current study the signal of benefit for AKI-D was strongest in this group of patients. Given the large number of surgeries complicated by AKI-D worldwide each year, we propose that such RCTs should be undertaken.

**Conclusions**

In this cohort study, preoperative ACEi/ARB use versus non-use was associated with a lower risk of AKI-D, and the association was primarily evident in patients with CKD. Large, multi-centre randomized trials are needed to inform optimal ACEi/ARB use in the peri-operative setting.

**Additional file**

Additional file 1: Additional details on research methods and results.

**Competing interests**

Amit Garg's institution received an unrestricted grant from Pfizer for research unrelated to the current project. All the authors declare no competing interests.

**Authors' contributions**

MS, AJ and AG conceived of the study and developed the study protocol. MS, AJ, SB, SC, PD, MI, JL, AM, NM, NP, CP, MP, SS, RW, MW, RW, DW and AG contributed to the study design. JL carried out the statistical analysis. MS drafted the manuscript. MS, AJ, SB, SC, PD, MI, JL, AM, MM, NP, CP, MP, SS, RW, MW, RW, DW and AG read, edited and approved the final manuscript.

**Acknowledgements**

This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions...
reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. We also thank Brogan Inc, Ottawa for use of its Drug Product and Therapeutic Class Database. Dr. Michael Walsh was supported by a New Investigator Award from the Kidney Research Scientist Core Education National Training (RESPECT) program. Dr. Amit X. Garg was supported by a Clinician Scientist Award from the Canadian Institutes of Health Research.

Author details
1 Divisions of Clinical Epidemiology and Internal Medicine, McGill University, Montreal, Canada.
1 Divider of Nephrology, Department of Medicine, Western University, London, Canada.
1 Institute for Clinical Evaluative Sciences, Ontario, Canada. 2Division of Nephrology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA.
1 Section of Nephrology, Yale University School of Medicine, New Haven, USA.
1 Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada.
1 Department of Medicine, University of Calgary, Hamilton, Canada. 2Division of Nephrology, University of Ottawa, Ottawa, Canada. 3Department of Medicine, Western University, London, Canada.
1 Division of Nephrology, Department of Medicine, University of Alberta, Edmonton, Canada.
1 Department of Family Medicine, McMaster University, Hamilton, Canada.
1 Division of Nephrology, Department of Medicine, McMaster University, Hamilton, Canada.
1 Department of Surgery, McMaster University, Hamilton, Canada.
1 Department of Anesthesia, University of Toronto, Toronto, Canada.
1 London Kidney Clinical Research Unit, Westminster, London Health Sciences Centre, Room ELL-101, 800 Commissioners Road East, London, Ontario N6A 4G5, Canada.

Received: 16 October 2013 Accepted: 28 March 2014
Published: 2 April 2014

References

1. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J. Independent association between acute renal failure and mortality following cardiac surgery. J Am Med Assoc 1998, 104:345–348.
2. Khetarpal S, Tremper KK, Englebre M, D’O’Reilly M, Shank AM, Netterman DM, Rosenberg AL, Swartz RD. Predictors of postoperative acute renal failure after noncardiac surgery in patients with previously normal renal function. Anesthesiology 2007, 107:892–902.
3. Molnar AO, Coca SG, Devereaux PJ, Jain AK, Kitchlu A, Luo J, Parkin CR, Paterson JM, Siddiqui N, Ward R, Walsh M, Garg AX. Statin use associates with a lower incidence of acute kidney injury after major elective surgery. J Am Soc Nephrol 2011, 22:839–946.
4. Weiser TG, Regenbogen SE, Thompson KD, Haynes AB, Lipsitz SR, Berry WR, Gawande AA. An estimation of the global volume of surgery: a modelling strategy based on available data. Lancet 2008, 372:139–144.
5. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Risk of acute kidney injury following cardiovascular surgery. Am J Med 2009, 127:3365–3370.
6. Abella BJ, Botelho M, Fernandes V, Barros H. Determinants of postoperative acute kidney injury. Crit Care Med 2009, 38:1379.
7. Khetarpal S, Tremper KK, Heung M, Rosenberg AL, Englebre M, Shank AM, Campbell DA. Jr. Development and validation of an acute kidney injury risk index for patients undergoing general surgery: results from a national data set. Anesthesiology 2009, 110:505–515.
8. Miceli A, Capoun R, Fino C, Narayan P, Brien BJ, Willison D, Grootendorst P, Cote J, Garg AX. Fibrin use and acute renal outcomes in elderly adults: a population-based study. Ann Intern Med 2012, 156:560–569.
9. Gill SS, Anderson GM, Fischer HD, Bell OM, Li P, Normand SL, Rochon PA. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med 2009, 169:867–873.
10. Austin PC, Daly PA, Tu JV. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J 2002, 144:290–296.
11. Setoguchi S, Glynn RJ, Avorn J, Mittleman MA, Levin R, Winkelmayer WC. Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol 2008, 51:1247–1254.
12. Rosenman DJ, McDonald DS, Ebert JO, Erwin PJ, Labella M, Montori VM. Clinical consequences of withholding versus administering renin-angiotensin-aldosterone system antagonists in the perioperative period. J Hosp Med 2008, 3:319–326.
13. Auron M, Harte B, Kamar A, Michota F. Renin-angiotensin system antagonists in the perioperative setting: clinical consequences and recommendations for practice. Postgrad Med 2011, 127:472–481.
14. Flesher LA, Beckman JA, Brown KA, Callens H, Chikofe E, Fleischmann KE, Freeman WF, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, Smith SC, Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Malmstrom R, O’Connor CF, Page RL, Tarkington LS et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007, 116:e418–e499.
15. Khetarpal S, Khodaparast O, Shanks A, D’O’Reilly M, Tremper KK. Chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy combined with diuretic therapy is associated with increased episodes of hypotension in noncardiac surgery. J Cardiothorac Vasc Anesth 2008, 22:180–186.

Setoguchi S, Glynn RJ, Avorn J, Mittleman MA, Levin R, Winkelmayer WC. Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol 2008, 51:1247–1254.

Auron M, Harte B, Kamar A, Michota F. Renin-angiotensin system antagonists in the perioperative setting: clinical consequences and recommendations for practice. Postgrad Med 2011, 127:472–481.

Flesher LA, Beckman JA, Brown KA, Callens H, Chikofe E, Fleischmann KE, Freeman WF, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, Smith SC, Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Malmstrom R, O’Connor CF, Page RL, Tarkington LS et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007, 116:e418–e499.

Khetarpal S, Khodaparast O, Shanks A, D’O’Reilly M, Tremper KK. Chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy combined with diuretic therapy is associated with increased episodes of hypotension in noncardiac surgery. J Cardiothorac Vasc Anesth 2008, 22:180–186.
29. Liu L, Reeder B, Shaib A, Mazagri R: Validity of stroke diagnosis on hospital discharge records in Saskatchewan, Canada: implications for stroke surveillance. Cerebrovasc Dis 1999, 9:224–230.

30. Ronksley PE, Tonelli M, Quan H, Manns BJ, James MT, Clement FM, Samuel S, Quinn RR, Ravani P, Brar SS, Hemmelgarn BR: Validating a case definition for chronic kidney disease using administrative data. Nephrol Dial Transplant 2012, 27(2):1832–1831.

31. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorenson HT: The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 2011, 11:83.

32. Walkar SS, Wald R, Chertow GM: Validity of international classification of diseases, ninth revision, clinical modification codes for acute renal failure. J Am Soc Nephrol 2006, 17:1688–1694.

33. Jha P, Deboer D, Sykora K, Naylor CD: Odds ratio, relative risk, absolute risk reduction, and the number needed to treat—which of these should we use? Value Health 2002, 5:431–436.

34. Mamdani M, Sykora K, Li P, Normand SL, Streiner DL, Austin PC, Rochon PA, Reader 2012, 27:1335–1342.

35. Mamdani M, Sykora K, Li P, Normand SL, Streiner DL, Austin PC, Rochon PA, Anderson GM: Reader’s guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ 2005, 330:960–962.

36. Schechtman E: Odds ratio, relative risk, absolute risk reduction, and the number needed to treat—which of these should we use? Value Health 2002, 5:431–436.

37. Ouzounian M, Buth KJ, Valeeva L, Morton CC, Hassan A, Ali IS: Impact of preoperative angiotensin-converting enzyme inhibitor use on clinical outcomes after cardiac surgery. Ann Thorac Surg 2012, 93:559–564.

38. Austin PC, Grootendorst P, Anderson GM: A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007, 26:794–793.

39. Glynn RJ, Schneeweiss S, Sturmer T: Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006, 98:253–259.

40. Barodka V, Silvestry S, Zhao N, Jiao X, Whellan DJ, Diehl J, Sun JZ: Angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001, 104:1985–1991.

41. Ahmed AK, Kamath NS, El KM, El Nahas AM: The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 2010, 25:3977–3982.

42. Cittanova ML, Zubicki A, Savu C, Montalvan C, Nefaa N, Zaier K, Riou B, Coriat P: Validating a case definition for chronic kidney disease using administrative data. Nephrol Dial Transplant 2012, 27(2):1832–1831.

43. Shay et al. BMC Nephrology 2014, 15:53 http://www.biomedcentral.com/1471-2369/15/53

Cite this article as: Shah et al.: Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis. BMC Nephrology 2014 15:53.